Prevention of sudden cardiac death by the wearable cardioverter defibrillator in a young patient with cardiac sarcoidosis

Andrié, René; Gaertner, Florian; Skowasch, Dirk

doi:10.1136/thoraxjnl-2016-208834

Cited by 4 publications

(3 citation statements)

References 1 publication

(2 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among CS patients, the occurrence of ventricular tachycardia/fibrillation (VT/VF) is elevated, as evidenced by an event rate of 7.1% per year of appropriate implantable cardioverter defibrillator (ICD) therapies [ 11 ]. A recently published case study involving a young CS patient has described use of the WCD to manage VT/VF and prevent sudden cardiac death (SCD) [ 12 ]. There are, however, few data to help with SCD risk stratification [ 13 ].…”

Section: Introductionmentioning

confidence: 99%

Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator

Skowasch

Ringquist²,

Nickenig

et al. 2018

PLoS ONE

Self Cite

View full text Add to dashboard Cite

BackgroundPatients with cardiac sarcoidosis are at increased risk of ventricular tachycardia/fibrillation.ObjectiveWe tested the hypothesis that the wearable cardioverter defibrillator can be used to mitigate the risk of sudden cardiac death among cardiac sarcoidosis patients.MethodsA retrospective review of the commercial database identified cardiac sarcoidosis patients who wore the wearable cardioverter defibrillator. Evidence for cardiac sarcoidosis diagnosis as well as demographic, co-morbidity and left ventricular ejection fraction were provided by patient clinical records. Clinical data also included daily wearable cardioverter defibrillator wear, shock treatment and survival information.ResultsThe wearable cardioverter defibrillator was worn by 46 cardiac sarcoidosis patients, 24 (52%) male. The median age was 48 years and median left ventricular ejection fraction was 30%. The wearable cardioverter defibrillator was worn a median of 23.6 hours each day. There were 11 ventricular tachycardia/fibrillation episodes occurring in 10 (22%) patients. Ventricular tachycardia/fibrillation occurred over a range of 1 to 79 days, median 24 days. First-shock success for conversion of ventricular tachycardia/fibrillation was 100%. Patient survival 24 hours after shock treatment was 100%. Follow up to determine the reason for discontinuing wearable cardioverter defibrillator use indicated that among shocked patients 7 received an implantable cardioverter defibrillator, 1 patient was admitted to the hospital ending in death 2 weeks after discontinuing wearable cardioverter defibrillator use, and 2 patients were lost to follow up. Among the not shocked patients, there were 16 who received an implantable cardioverter defibrillator while 7 achieved improved left ventricular ejection fraction.ConclusionManagement of sudden cardiac death among cardiac sarcoidosis patients was aided by the wearable cardioverter defibrillator resulting in successful termination of ventricular tachycardia/fibrillation upon delivery of shock.

show abstract

Section: Introductionmentioning

confidence: 99%

Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator

Skowasch

Ringquist²,

Nickenig

et al. 2018

PLoS ONE

Self Cite

View full text Add to dashboard Cite

show abstract

“…Given the potential for serious VA and sudden death, all sarcoid patients with severe VA, heart block, or cardiomyopathy should be considered for ICD in addition to medical therapy. 99,154,230,231,[237][238][239][240][241] Society Guidelines cited primary prevention ICD implantation as a class IIA recommendation (level C) for patients with cardiac sarcoidosis. 242 A multicenter study (13 sites) followed 235 patients with cardiac sarcoidosis post-ICD placement.…”

Section: Our Approach To Treatment Of Cardiac Sarcoidosismentioning

confidence: 99%

Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and Treatment

Sayah

Bradfield²,

Moriarty

et al. 2017

Semin Respir Crit Care Med

View full text Add to dashboard Cite

show abstract

“…Amongst Cardiac sarcoidosis disease patients, the existence of ventricular tachycardia or ventricular fibrillation (VT/VF) is raised, as evinced by an incident degree of seven percent yearly of proper implantable device cardioverter defibrillator treatments [11]. A lately available case study of young Cardiac sarcoidosis disease patient has labelled the WCD use to achieve ventricular tachycardia or ventricular fibrillation and avert abrupt heart attack (HA) [12]. The limited data help with abrupt heart attack threat assumptions [13].…”

Section: Introductionmentioning

confidence: 99%

Machine Learning Models Predicting the Survival of Abrupt Heart Attack in Cardiac Sarcoidosis Disease u sing the Wearable Device

Shafi*,

Krishna

2020

IJITEE

View full text Add to dashboard Cite

Wearable technology has countless prospects of remodelling healthcare establishment and also medical education. Cardiac sarcoidosis disease (CS) is a sporadic illness in which white blood cells (WBC) clusters known as granulomas, form as heart tissue. Cardiac sarcoidosis disease (CS) Patients are at high threat of ventricular tachycardia or ventricular fibrillation (VT/VF). Wearable cardioverter defibrillator device is introduced which helps to alleviate the abrupt heart attack risk amid patients of cardiac sarcoidosis. A reflective evaluation of the commercial record acknowledged patients of cardiac sarcoidosis disease who sported the wearable cardioverter defibrillator (WCD). ML models are applied to get accurate predictions to motivate WCD wear ability. The wearable device cardioverter defibrillator (WCD) was worn by forty six patients of cardiac sarcoidosis disease in which 22(48%) female, male 24 (52%). The wearable cardioverter defibrillator (WCD) was sported hours about 23.6 median daily. Nearby eleven ventricular tachycardia or ventricular fibrillation (VT/VF) incidents occur in ten patients (22%). Ventricular tachycardia or ventricular fibrillation (VT/VF) happened over a series of (1-79) days, median of twenty-four days. 1st- heart attack success for ventricular tachycardia or ventricular fibrillation (VT/VF) conversion was hundred percent. Survival of Patient in twenty four hours after treatment of attack was hundred percent. To regulate the discontinuing cause for wearable device cardioverter defibrillator (WCD) use specified that among seven attacked patients received ICD, one patient was died two weeks later discontinuing the use of wearable cardioverter defibrillator device (WCD), and two patients were absent to track. Sixteen were not attacked patients, who obtained an implantable cardioverter defibrillator (ICD) while seven of them attained and improved left ventricular ejection fraction (LVEF). Abrupt heart attack (HA) management amongst patients of cardiac sarcoidosis disease (CS) was assisted by wearable device cardioverter defibrillator (WCD) ensuing in positive ventricular tachycardia or ventricular fibrillation (VT/VF) termination upon attack delivery. In this paper, the dataset is retrieved from google dataset search and evaluated on various ML models to predict the survival of the patients Receiving ICD while wearing WCD as well as evaluating the developed model performance and to identify the best applicable model. Dataset is primarily processed and nursed to many machine learning classifiers like KNN, SVM, Perceptron, Random Forest, Decision Trees (DT), Logistic Expression, SGD, and Naïve Basis. Cross-validation is smeared, training is performed so that new machine learning models are established and verified. The outcomes found are assessed on many factors such as Accuracy, Misclassification Rate, True Positive Rate, True Negative Rate, Precision, Prevalence, False Positive rate taken to build the model. Result analysis reveals that among all the classifiers SVM and KNN best model acquiescent high and precise outcomes.

show abstract

Prevention of sudden cardiac death by the wearable cardioverter defibrillator in a young patient with cardiac sarcoidosis

Cited by 4 publications

References 1 publication

Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator

Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator

Cardiac Involvement in Sarcoidosis: Evolving Concepts in Diagnosis and Treatment

Machine Learning Models Predicting the Survival of Abrupt Heart Attack in Cardiac Sarcoidosis Disease u sing the Wearable Device

Contact Info

Product

Resources

About